Surmodics, Inc. (SRDX)

Market Cap	375.69M
Revenue (ttm)	138.20M
Net Income (ttm)	5.52M
Shares Out	14.24M
EPS (ttm)	0.39
PE Ratio	67.67
Forward PE	81.97
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,566
Open	26.52
Previous Close	26.52
Day's Range	26.31 - 26.95
52-Week Range	16.79 - 39.41
Beta	1.02
Analysts	Strong Buy
Price Target	59.00 (+123.57%)
Earnings Date	Apr 29, 2024

About SRDX

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Mar 4, 1998
• Employees: 376
• Stock Exchange: NASDAQ
• Ticker Symbol: SRDX

Financial Performance

In 2023, Surmodics's revenue was $132.58 million, an increase of 32.65% compared to the previous year's $99.95 million. Losses were -$1.54 million, -94.37% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for SRDX stock is "Strong Buy." The 12-month stock price forecast is $59.0, which is an increase of 123.57% from the latest price.

Price Target

$59.0

(123.57% upside)

Analyst Consensus: Strong Buy